FDA approves Sanofi's factor VIII hemophilia A drug
The newly approved drug — which has the factor VIII focus spelled out inside its branded name, Altuviiio — works to replace the missing or defective factor VIII in hemophilia A in a once-weekly treatment. It wasn’t immediately clear Thursday morning how Sanofi plans to price the drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.